<!doctype html>


<html class="no-js" dir="ltr" lang="en" xmlns="http://www.w3.org/1999/xhtml">


<!-- Mirrored from www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/compliance-enforcement/guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-consultation.html by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 03 Apr 2025 21:45:45 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head prefix="og: http://ogp.me/ns#">
    
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
<meta charset="utf-8"/>
<title>Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101) - Canada.ca</title>
<meta content="width=device-width,initial-scale=1" name="viewport"/>


	<link rel="schema.dcterms" href="http://purl.org/dc/terms/"/>
	<link rel="canonical" href="guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-cons"/>
    <link rel="alternate" hreflang="en" href="guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-cons"/>
	
        <link rel="alternate" hreflang="fr" href="https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/participation-public-consultations/conformite-application-loi/guide-classification-observations-inspections-etablissements-cellules-tissus-organes-0101-consultation.html"/>
	
	
		<meta name="description" content="2011 Health Canada consultation document (comment period ending February 21, 2012)"/>
	
	
		<meta name="keywords" content="consultations, guidance, observations, inspection, cells, tissues, organs establishments, GUI-0101, risk classification, compliance rating, CTO regulations"/>
	
	
		<meta name="author" content="Health Canada"/>
	
	
		<meta name="dcterms.title" content="Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101)"/>
	
	
		<meta name="dcterms.description" content="2011 Health Canada consultation document (comment period ending February 21, 2012)"/>
	
	
		<meta name="dcterms.creator" content="Health Canada"/>
	
	
	
		<meta name="dcterms.language" title="ISO639-2/T" content="eng"/>
	
	
		<meta name="dcterms.subject" title="gccore" content="Health and Safety"/>
	
	
		<meta name="dcterms.issued" title="W3CDTF" content="2011-11-03"/>
	
	
		<meta name="dcterms.modified" title="W3CDTF" content="2011-12-08"/>
	
	
		<meta name="dcterms.audience" content="general public"/>
	
	
		<meta name="dcterms.spatial" content="Canada"/>
	
	
		<meta name="dcterms.type" content="guidance"/>
	
	
	
	
	
		<meta name="dcterms.identifier" content="Health_Canada"/>
	
	
	
        



	<meta prefix="fb: https://www.facebook.com/2008/fbml" property="fb:pages" content="378967748836213, 160339344047502, 184605778338568, 237796269600506, 10860597051, 14498271095, 209857686718, 160504807323251, 111156792247197, 113429762015861, 502566449790031, 312292485564363, 1471831713076413, 22724568071, 17294463927, 1442463402719857, 247990812241506, 730097607131117, 1142481292546228, 1765602380419601, 131514060764735, 307780276294187, 427238637642566, 525934210910141, 1016214671785090, 192657607776229, 586856208161152, 1146080748799944, 408143085978521, 490290084411688, 163828286987751, 565688503775086, 460123390028, 318424514044, 632493333805962, 370233926766473, 173004244677, 1562729973959056, 362400293941960, 769857139754987, 167891083224996, 466882737009651, 126404198009505, 135409166525475, 664638680273646, 169011506491295, 217171551640146, 182842831756930, 1464645710444681, 218822426028, 218740415905, 123326971154939, 125058490980757, 1062292210514762, 1768389106741505, 310939332270090, 285960408117397, 985916134909087, 655533774808209, 1522633664630497, 686814348097821, 230798677012118, 320520588000085, 103201203106202, 273375356172196, 61263506236, 353102841161, 1061339807224729, 1090791104267764, 395867780593657, 1597876400459657, 388427768185631, 937815283021844, 207409132619743, 1952090675003143, 206529629372368, 218566908564369, 175257766291975, 118472908172897, 767088219985590, 478573952173735, 465264530180856, 317418191615817, 428040827230778, 222493134493922, 196833853688656, 194633827256676, 252002641498535, 398018420213195, 265626156847421, 202442683196210, 384350631577399, 385499078129720, 178433945604162, 398240836869162, 326182960762584, 354672164565195, 375081249171867, 333050716732105, 118996871563050, 240349086055056, 119579301504003, 185184131584797, 333647780005544, 306255172770146, 369589566399283, 117461228379000, 349774478396157, 201995959908210, 307017162692056, 145928592172074, 122656527842056">


	


    


	<script src="../../../../../../../assets.adobedtm.com/be5dfd287373/abb618326704/launch-3eac5e076135.min.js"></script>










<link rel="stylesheet" href="../../../../../../../use.fontawesome.com/releases/v5.15.4/css/all.css" integrity="sha256-mUZM63G8m73Mcidfrv5E+Y61y7a12O5mW4ezU3bxqW4=" crossorigin="anonymous"/>
<link rel="stylesheet" href="../../../../../../etc/designs/canada/wet-boew/css/theme.min.css"/>
<link href="https://www.canada.ca/etc/designs/canada/wet-boew/assets/favicon.ico" rel="icon" type="image/x-icon"/>
<noscript><link rel="stylesheet" href="../../../../../../etc/designs/canada/wet-boew/css/noscript.min.css"/></noscript>







                              <script>!function(a){var e="https://s.go-mpulse.net/boomerang/",t="addEventListener";if("False"=="True")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="KBFUZ-C9D7G-RB8SX-GRGEN-HGMC9",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement("iframe");if(a[t])a[t]("load",n,!1);else if(a.attachEvent)a.attachEvent("onload",n);r.src="javascript:void(0)",r.title="",r.role="presentation",(r.frameElement||r).style.cssText="width:0;height:0;border:0;display:none;",o=document.getElementsByTagName("script")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src="javascript:var d=document.open();d.domain='"+i+"';void(0);",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement("script");if(i)this.domain=i;a.id="boomr-if-as",a.src=e+"KBFUZ-C9D7G-RB8SX-GRGEN-HGMC9",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write("<bo"+'dy onload="document._l();">'),_.close()}}(),"".length>0)if(a&&"performance"in a&&a.performance&&"function"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=""=="true"?1:0,t="",n="jihjtrvydlamaz7oxdta-f-aa0c9afae-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,_={"ak.v":"39","ak.cp":"780901","ak.ai":parseInt("231651",10),"ak.ol":"0","ak.cr":3,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"bc98d0b","ak.r":47855,"ak.a2":e,"ak.m":"dscb","ak.n":"essl","ak.bpcip":"74.14.153.0","ak.cport":51792,"ak.gh":"23.42.150.4","ak.quicv":"","ak.tlsv":"tls1.2","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"bbr","ak.t":"1743698150","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==uaGtDLGLdTMNG3kxQwrwObGS1/a3KvsYusT6K0rlfXBVwrDh3p0STTiRgVKCktHkvVnCXif6KmNkmZePDtxv9TVxEF5SaVanSI34nEvXNNAXQW5KPb9UPFjjdXfYu1xCZJszZ3cbG9RKcEkG5vXRdjMKn1CAJXSwDAAuqNl9yoZIXVFAp8RCRz+QPyLirZrC9Nk+zKtKF4eGiDz3OWD9n6uOWQcMcZaCIxCQ9C+Y3MIqCHhmw5vA74Qzes3Xe9nSy3b1BpVIVg3w+xi6HDWH+Nitlnmo00QNTZ0jNbQcPpxsxMIJHVpSU7R9Fa6FpHP0cPHL/TUtKZ46k/4K8k+qge3nenyydySrDvRc122VDC0d8XFe9SGOwoiXljusIr/I1ENTxY9yPvp99MDpY6D49Dds38J6+qlmJ2uMbU9uDa4=","ak.pv":"794","ak.dpoabenc":"","ak.tf":i};if(""!==t)_["ak.ruds"]=t;var o={i:!1,av:function(e){var t="http.initiator";if(e&&(!e[t]||"spa_hard"===e[t]))_["ak.feo"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","https://www.canada.ca/en/errors/404.html","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","https://www.canada.ca/en/errors/404.html","ak.tf"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a("before_beacon",o.av,null,null),a("onbeacon",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script></head>

<body vocab="http://schema.org/" typeof="WebPage" resource="#wb-webpage">

    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    
        
        
        <div class="global-header"><nav><ul id="wb-tphp">
	<li class="wb-slc"><a class="wb-sl" href="#wb-cont">Skip to main content</a></li>
	<li class="wb-slc"><a class="wb-sl" href="#wb-info">Skip to &#34;About government&#34;</a></li>
	<li class="wb-slc"><a class="wb-sl" href="#wb-sec">Skip to section menu</a></li>
</ul></nav>

<header>
	<div id="wb-bnr" class="container">
		<div class="row">
			
			<section id="wb-lng" class="col-xs-3 col-sm-12 pull-right text-right">
    <h2 class="wb-inv">Language selection</h2>
    <div class="row">
        <div class="col-md-12">
            <ul class="list-inline mrgn-bttm-0">
                <li>
                    <a lang="fr" href="https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/participation-public-consultations/conformite-application-loi/guide-classification-observations-inspections-etablissements-cellules-tissus-organes-0101-consultation.html">
                        
                            <span class="hidden-xs" translate="no">Fran&ccedil;ais</span>
                            <abbr title="Fran&ccedil;ais" class="visible-xs h3 mrgn-tp-sm mrgn-bttm-0 text-uppercase" translate="no">fr</abbr>
                        
                        
                    </a>
                </li>
                
                
            </ul>
        </div>
    </div>
</section>
				<div class="brand col-xs-9 col-sm-5 col-md-4" property="publisher" resource="#wb-publisher" typeof="GovernmentOrganization">
					
                    
					
						
						<a href="https://www.canada.ca/en.html" property="url">
							<img src="https://www.canada.ca/etc/designs/canada/wet-boew/assets/sig-blk-en.svg" alt="Government of Canada" property="logo"/>
							<span class="wb-inv"> /
								
								<span lang="fr">Gouvernement du Canada</span>
							</span>
						</a>
					
					<meta property="name" content="Government of Canada"/>
					<meta property="areaServed" typeof="Country" content="Canada"/>
					<link property="logo" href="https://www.canada.ca/etc/designs/canada/wet-boew/assets/wmms-blk.svg"/>
				</div>
				<section id="wb-srch" class="col-lg-offset-4 col-md-offset-4 col-sm-offset-2 col-xs-12 col-sm-5 col-md-4">
					<h2>Search</h2>
					
<form action="https://www.canada.ca/en/sr/srb.html" method="get" name="cse-search-box" role="search">
	<div class="form-group wb-srch-qry">
		<label for="wb-srch-q" class="wb-inv">Search Canada.ca</label>
		
			<input id="wb-srch-q" list="wb-srch-q-ac" class="wb-srch-q form-control" name="q" type="search" value="" size="34" maxlength="170" placeholder="Search Canada.ca"/>
		    
		

		<datalist id="wb-srch-q-ac">
		</datalist>
	</div>
	<div class="form-group submit">
	<button type="submit" id="wb-srch-sub" class="btn btn-primary btn-small" name="wb-srch-sub"><span class="glyphicon-search glyphicon"></span><span class="wb-inv">Search</span></button>
	</div>
</form>

				</section>
		</div>
	</div>
	<hr/>
	
	<div class="container"><div class="row">
		
        <div class="col-md-8">
        <nav class="gcweb-menu" typeof="SiteNavigationElement">
		<h2 class="wb-inv">Menu</h2>
		<button type="button" aria-haspopup="true" aria-expanded="false"><span class="wb-inv">Main </span>Menu <span class="expicon glyphicon glyphicon-chevron-down"></span></button>
<ul role="menu" aria-orientation="vertical" data-ajax-replace="/content/dam/canada/sitemenu/sitemenu-v2-en.html">
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/jobs.html">Jobs and the workplace</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://travel.gc.ca/">Travel and tourism</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/business.html">Business and industry</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/health.html">Health</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/science.html">Science and innovation</a></li>
</ul>

		
        </nav>   
        </div>
		
		
		
    </div></div>
	
		<nav id="wb-bc" property="breadcrumb"><h2 class="wb-inv">You are here:</h2><div class="container"><ol class="breadcrumb">
<li><a href='https://www.canada.ca/en.html'>Canada.ca</a></li>
<li><a href='https://www.canada.ca/en/government/dept.html'>Departments and agencies</a></li>
<li><a href='https://www.canada.ca/en/health-canada.html'>Health Canada</a></li>
<li><a href='../../../drugs-health-products.html'>Drugs and health products</a></li>
<li><a href='../../public-involvement-consultations.html'>Public Involvement and Consultations</a></li>
<li><a href='../compliance-enforcement.html'>Compliance and Enforcement</a></li>
</ol></div></nav>


	

  
</header>
</div>

    

</div>

    




	









<div class="container">
    <div class="row">
        <main property="mainContentOfPage" resource="#wb-main" typeof="WebPageElement" class="col-md-9 col-md-push-3">
            

    <h1 property="name" id="wb-cont" dir="ltr">
Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101)</h1>




                 
                    <div><div class="mwsbodytext text parbase section">
    

    
        <a id="cont" name="cont"></a>
    


</div>
<div class="mwsalerts section">


	
		


	

<section class="alert borderRed alert alert-danger">
	<h3> </h3>
	<p>The online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public and contains the content that was open for submissions during the consultation period. The new guides will be posted when the documents are finalized.</p>
</section>



	

</div>
<div class="mwstext section"><div class="icon mrgn-bttm-sm mrgn-tp-sm">
 <a href="https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/consultation/compli-conform/2011-gui-0101_pdf_eng.pdf" title="Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101) (Portable Document Format Version - 237 Kilobytes)">(PDF Version - 237 K)</a>
</div></div>
<div class="mwsbodytext text parbase section">
    

    
        <p><a href="http://www.hc-sc.gc.ca/contact/dhp-mps/hpfb-dgpsa/insp-btox-stox-eng.php">Contact Information</a></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Letter</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Our Mandate</strong>:<br> To manage and deliver a national compliance and enforcement program for blood and donor semen; cells, tissues and organs; drugs (human and veterinary); medical devices and natural health products, collaborating with and across, all regions.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Supersedes: Draft for comments</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Date issued: Draft for comments</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Date of implementation: Draft for comments</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2>Disclaimer</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em>This document does not constitute part of the Food and Drugs Act (Act) or its associated Regulations and in the event of any inconsistency or conflict between that Act or Regulations and this document, the Act or the Regulations take precedence. This document is an administrative document that is intended to facilitate compliance by the regulated party with the Act, the Regulations and the applicable administrative policies. This document is not intended to provide legal advice regarding the interpretation of the Act or Regulations. If a regulated party has questions about their legal obligations or responsibilities under the Act or Regulations, they should seek the advice of legal counsel.</em></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2>Table of contents</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="list-unstyled"> 
 <li><a href="#a1.0">1.0 Purpose</a></li> 
 <li><a href="#a2.0">2.0 Background</a></li> 
 <li><a href="#a3.0">3.0 Scope</a></li> 
 <li><a href="#a4.0">4.0 Definitions and Acronyms</a></li> 
 <li><a href="#a5.0">5.0 Guide</a> 
  <ul class="lst-none"> 
   <li><a href="#a5.1">5.1 Assigning a Risk Classification to an Observations</a></li> 
   <li><a href="#a5.2">5.2 Determining the Establishment's Overall Compliance Rating</a></li> 
  </ul> </li> 
 <li><a href="#a6.0">6.0 References</a></li> 
 <li><a href="#app1">Appendix: Potential Observations and Assigned Ratings</a></li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a1.0">1.0 Purpose</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>This document is an administrative tool and is intended to:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>Assist in the classification of observations made during inspection of Cells, Tissues and Organs (<abbr>CTO</abbr>) establishments.</li> 
 <li>Promote uniformity in the assignment of ratings to individual observations, and to overall inspection ratings of the <abbr>CTO</abbr> establishments.</li> 
 <li>Provide examples of situations of non-compliance with the <a href="http://laws-lois.justice.gc.ca/eng/regulations/SOR-2007-118/index.html" title="Safety of Human Cells, Tissues and Organs for Transplantation Regulations (CTO Regulations) (external link)"><em>Safety of Human Cells, Tissues and Organs for Transplantation Regulations</em> (<abbr>CTO</abbr> Regulations)</a>.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>This document should be read in combination with the <em>Food and Drugs Act</em> (Act), <abbr>CTO</abbr> Regulations, the referenced sections of the General Standard <abbr>CAN/CSA</abbr> Z900.1 entitled, <em>Cells, Tissues, and Organs for Transplantation and Assisted Reproduction: General Requirements</em>, along with the subset of National Standards for lymphohematopoietic cells, perfusable organs, tissue and ocular tissues and the <em>Guidance Document for Cells, Tissues and Organs Establishments</em><em> - Safety of Human Cell, Tissue and Organ for Transplantation</em>.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a2.0">2.0 Background</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>The <abbr>CTO</abbr> Regulations were made pursuant to the Act. The <abbr>CTO</abbr> Regulations directly reference sections of the National Standard thus making them mandatory. The purpose of this regulatory initiative is to minimize the potential health risks to Canadian recipients of human cells, tissues and organs. The <abbr>CTO</abbr> Regulations address safety in the processing and handling of these products, resulting in improved protection of the health and safety of Canadian transplant recipients. The <abbr>CTO</abbr> Regulations were published on June 27, 2007 and came into force on December 7, 2007, except for subsection 26(1) which came into force on June 7, 2008.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Health Canada conducts inspections of <abbr>CTO</abbr> establishments under the authority of Section 23 of the Act. Inspections are an important part of a national compliance and enforcement program.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>During the first round of inspections, Health Canada inspected Canadian registered <abbr>CTO</abbr> programs to assess their compliance with the <abbr>CTO</abbr> Regulations and assigned an overall rating to each establishment.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Effective April 2012 individual observations will also be assigned a classification (e.g. critical, major or minor). This is in addition to the overall rating (e.g. Compliant or Non-Compliant) that will be assigned following an inspection. The intention is to provide more information to establishments with regards to their level of compliance with the <abbr>CTO</abbr> Regulations. All ratings will be assigned in accordance with the principles and guidelines set forth in this document.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a3.0">3.0 Scope</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>This guidance document applies to inspections of all <abbr>CTO</abbr> establishments regulated under the <abbr>CTO</abbr> Regulations. The attached appendix provides examples of situations or observations and their assigned risk classification. Classification of an observation is determined by the inspector using his or her judgment in consultation with this document and other relevant documents and information. Please note that the list in the appendix is not exhaustive and additional situations or observations may be added where appropriate.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a4.0">4.0 Definitions and Acronyms</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <dl class="data-spacing-bottom"> 
 <dt>
  Inspection:
 </dt> 
 <dd>
  On-site monitoring and assessment against the applicable requirements of the Act and its associated Regulations. Inspections are routinely conducted on a predetermined cycle or as required to assess compliance.
 </dd> 
 <dt>
  Observation:
 </dt> 
 <dd>
  A deviation from or deficiency in compliance with the Act or the 
  <abbr>CTO</abbr> Regulations found during the inspection of a 
  <abbr>CTO</abbr> establishment. An observation is classified in accordance with the level of risk associated with the deficiency. All observations must be documented in the inspection report (
  <strong>Exit Notice</strong>).
  <br><br> The observations are classified as Critical, Major or Minor.
 </dd> 
 <dt>
  Critical observation (Risk 1):
 </dt> 
 <dd> 
  <ul> 
   <li>Any observation that directly affects the safety of the product(s) and is likely to result in an immediate or latent health risk to the recipient; or</li> 
   <li>Fraud, misrepresentation or falsification of product(s) or data.</li> 
  </ul> 
 </dd> 
 <dt>
  Major observation (Risk 2):
 </dt> 
 <dd> 
  <ul> 
   <li>Any observation that potentially affects the safety of the product(s) and could result in an immediate or latent health risk to the recipient.</li> 
  </ul> 
 </dd> 
 <dt>
  Minor observation (Risk 3):
 </dt> 
 <dd> 
  <ul> 
   <li>Any observation that has low or negligible impact on the safety of the product(s).</li> 
  </ul> All observations cited in the Exit Notice will be assigned a numerical rating based on their classification: Risk 1 for Critical observations, Risk 2 for Major observations and Risk 3 for Minor observations.
 </dd> 
 <dt>
  C (Compliant):
 </dt> 
 <dd>
  At the time of the inspection, the regulated party has demonstrated that the activities it conducts are in compliance with the Act and its associated Regulations.
  <br><br><em><strong>Disclaimer - </strong>A Compliant rating does not mean that there are no observations or corrective actions required</em>.
 </dd> 
 <dt>
  <abbr>NC</abbr> (Non-compliant):
 </dt> 
 <dd>
  At the time of the inspection, the regulated party has not demonstrated that the activities it conducts are in compliance with the Act and its associated Regulations.
 </dd> 
</dl>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a5.0">5.0 Guide</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h3 id="a5.1">5.1 Assigning a Risk Classification to an Observations</h3>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Observations are classified as Critical, Major or Minor. The classification will be assigned based on the impact on the safety of the <abbr>CTO.</abbr> The following are examples of criteria that are taken into consideration:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>potential or immediate health risk;</li> 
 <li>nature of the non-compliance;</li> 
 <li>number of occurrences of a particular non-compliant issue; and</li> 
 <li>context of the situation</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>The <a href="#app1">Appendix</a> lists examples of situations that will lead to an observation. Although the specific examples given in the Appendix are assigned a particular rating, the same situation could be assigned a higher or lower rating depending on the nature and extent of the deficiency. The examples are intended to illustrate the process by which an inspector assigns a rating to his or her observations and are not intended to limit the discretion of an inspector in determining compliance with the Act and <abbr>CTO</abbr> Regulations. For example, observations that are repeated from previous inspection(s) may be assigned a different classification than referenced in the Appendix.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h3 id="a5.2">5.2 Determining the Establishment's Overall Compliance Rating</h3>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>The inspector will assign an overall rating of compliant or non-compliant as defined in section 4.0 of this document.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Generally the following criteria may apply when assessing the overall compliance rating;</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Compliant (C): </strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>No observations are made.</li> 
 <li>Only Minor observations are made.</li> 
 <li>A few Major observations are made and immediate corrective actions have been implemented when required.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Non-Compliant (<abbr>NC</abbr>):</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>One or more Critical observations are made.</li> 
 <li>Several Major observations are made which indicate that the establishment does not adequately control its regulated activities.</li> 
 <li>Failure to implement corrective measures for Critical or Major observations made in previous inspection.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>When a Critical observation is noted during an inspection, Health Canada will bring this serious situation will be brought to the attention of the establishment's Medical Director and/or qualified staff. The establishment will be duly informed that this may result in an "NC" rating. An action plan specifying corrective measures to be taken as well as the time frame necessary to implement these actions will be requested. An <abbr>NC</abbr> rating will have serious consequences for an establishment and may result in the cancellation of the registration of the <abbr>CTO</abbr> establishment. Enforcement actions will be taken as required and in accordance with Health Canada's<em> <a href="../../compliance-enforcement/good-manufacturing-practices/policies-standards/compliance-enforcement-policy-0001.html">Compliance and Enforcement Policy, <abbr>POL-0001</abbr></a></em>.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="a6.0">6.0 References</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>&nbsp;<a href="http://laws-lois.justice.gc.ca/eng/regulations/SOR-2007-118/index.html" title="Safety of Human Cells, Tissues and Organs for Transplantation Regulations (CTO Regulations) (external link)"><em>Safety of Human Cells, Tissues and Organs for Transplantation Regulations (<abbr>CTO</abbr> Regulations)</em></a>.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><a href="../../biologics-radiopharmaceuticals-genetic-therapie/regulatory-initiatives/cells-tissues-organs/guidance-document-safety-human-cells-tissues-organs-trans">Guidance Document for Cells, Tissues and Organs Establishments - Safety of Human Cells, Tissues and Organs for Transplantation</a>.</em></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>National Standard of Canada <abbr>CAN/CSA-Z900.1</abbr> entitled <em>Cells, Tissues, and Organs for Transplantation and Assisted Reproduction: General Requirements.</em></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>National Standard of Canada <abbr>CAN/CSA-Z900.2.2</abbr> entitled, <em>Tissues for Transplantation</em>.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>National Standard of Canada <abbr>CAN/CSA-Z900.2.3</abbr> entitled, <em>Perfusable Organs for Transplantation.</em></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>National Standard of Canada <abbr>CAN/CSA-Z900.2.4</abbr> entitled, <em>Ocular Tissues for Transplantation.</em></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>National Standard of Canada <abbr>CAN/CSA-Z900.2.5</abbr> entitled, <em>Lymphohematopoietic Cells for Transplantation</em>.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h2 id="app1">Appendix: Potential Observations and Assigned Ratings</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Prohibition (Section 4)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>An establishment transplanted a CTO that was not determined safe for transplantation.</li> 
 <li>An establishment transplanted tissues that were not processed by a registered establishment.</li> 
 <li>An establishment imported tissues that were not processed by a registered establishment.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Registration (Sections 5 to 14)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The establishment did not register all the types of CTO that they were processing.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The establishment did not notify the Minister in writing within the required timeframe, of the changes in the information provided in the registration.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Source Establishment (Section 15) </strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major: </strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>There was no documented evidence to indicate that the source establishment reviewed the processing activities performed by other entities on their behalf for completeness and compliance with the CTO Regulations.</li> 
 <li>There was no documented evidence that the donor suitability assessment was reviewed by the source establishment to determine that the CTO were safe for transplantation.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - General (Sections 16-17)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>No documented evidence to demonstrate validation of activities, processes or technical procedures where necessary.</li> 
 <li>Although the validation study was completed, not all parameters or products were included.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>Although the validation data was performed by qualified staff, there was no evidence that a final review was completed.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - Donor Suitability Assessment (Sections 18 to 23)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>There was no evidence that a physical exam was performed.</li> 
 <li>There was no evidence to indicate that a required infectious disease marker test was performed, yet the CTO from the donor were distributed.</li> 
 <li>There was no evidence that the donors were assessed against all exclusion criteria.</li> 
 <li>There was no evidence that the minimal serological testing was conducted within the required timeframe.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>The physical examination did not address all the requirements of section 13.2 of the CSA General Standard CAN/CSA-Z900.1.</li> 
 <li>The Donor Medical Social History Questionnaire included all the questions required by the exclusion criteria; however a response was not recorded for some of the questions.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - Retrieval (Section 24)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The retrieval time exceeded the established maximum interval between the cardiac asystole of the donor and the retrieval of the tissue.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - Testing (Sections 25 to 27)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The test kit that was used for donor testing was not licensed.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The test kit that was used for testing tissue donors was licensed as a diagnostic test kit rather than for donor screening as required.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - Packaging and Labelling (Sections 28 to 33)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The tissue bank did not include the donor identification code on the package insert and on the interior label as required.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The donor identification code was present on the interior label but not on the package insert when it was distributed from the tissue bank to other establishments.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>The contact information of the transplant Establishment was not identified on the exterior label, as required; however, the retrieval establishment, the source establishment and the transplant establishment are located within the same hospital.</li> 
 <li>There was no process in place to verify if the packaging material is free of damage.</li> 
 <li>Although exceptional distribution was used, the package insert did not include the statement "For Exceptional Distribution", the reason for exceptional distribution or how the cells did not meet the requirements of the CTO Regulations, as required. All other provisions of the exceptional distribution requirements were met.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Processing - Quarantine (Section 34)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>Although the donor suitability assessment was completed, there was no evidence to indicate that the processing records were reviewed for completeness and compliance with the <em>Regulations </em>and the standard operating procedures prior to the release of tissues from quarantine.</li> 
 <li>Tissues from a living donor were not quarantined for at least 180 days when the initial testing did not include nucleic acid testing (NAT) for HIV-1 and HCV.</li> 
 <li>The stored cord blood unit was not designated as quarantined although it had not been determined safe for transplantation under the CTO Regulations.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>The final report verifying bacteriological test result was not found in the donor file; however another copy of that report was obtained from the lab during the inspection.</li> 
 <li>Although qualified staff verified and accepted each of the donor suitability criterion, there was no process and/or control in place to ensure that the final donor suitability assessment was performed.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Storage (Sections 35 - 39)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The establishment did not take action following a significant deviation of temperature range in the released tissue freezer.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>Records indicate that the temperature of the quarantine and release storage equipment was not consistently monitored to ensure the acceptable temperature range was maintained.</li> 
 <li>Autologous tissues were stored with released allogeneic tissues without the autologous tissues being clearly labelled "For autologous use only".</li> 
 <li>CTO were stored in a room that was not being monitored to ensure that the appropriate environmental conditions were being maintained as per the requirements specific to the CTO.</li> 
 <li>There were no records to indicate that the time period used to store adjunct vessels, which were not used immediately in the organ transplantation, had been determined based on scientific evidence.</li> 
 <li>The tissue storage area was not secured to prevent the entry of unauthorized persons.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The quarantine and release freezers were monitored daily; however the documentation of the preventative maintenance program was not available for review.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Exceptional Distribution (Sections 40 - 42)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>There was no evidence to indicate that the source establishment distributed the tissue under the exceptional distribution provisions where required by the CTO Regulations.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The notice of Exceptional Distribution did not include the name of the transplant establishment.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Error, Accident and Adverse Reaction Investigation and Reporting (Sections 43 - 54)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>An error and accident investigation related to an unexpected adverse reaction involving a transmission of an infectious disease was not initiated by the source establishment.</li> 
 <li>Tissues were released from quarantine prior to the completion of the error and accident investigation.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>Although errors and accidents related to transmissible disease testing were investigated, the detailed final report was not submitted to the Minister by the source establishment.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Records (Section 55 - 63)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>There was no record that donor suitability assessment was completed.</li> 
 <li>There was no record identifying to which establishment the adjunct vessels were distributed.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The tissue retrieval form was completed by an employee not directly involved in the retrieval procedure.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>The donor suitability documentation received by fax was not legible. The information was verified verbally but not documented.</li> 
 <li>Shipping records of the distributed tissues were not consistently retained by the establishment.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Personnel, Facilities, Equipment and Supplies (Section 64 - 69)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>There was no documentation for the installation qualification of the newly acquired automated system used to process cord blood.</li> 
 <li>There were no training records or competency evaluations for staff performing the regulated activities in the establishment.</li> 
 <li>The insulated box containing the collection kit for cord blood has not been adequately qualified for the maintenance of appropriate environmental conditions.</li> 
 <li>The room where aseptic processing activities were being performed was not subject to microbiological monitoring and control.</li> 
 <li>The expiry date of critical supplies was not strictly observed.</li> 
 <li>The refrigerator used to store the tissues for transplantation was not being monitored to ensure that appropriate environmental conditions were maintained.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The training records were incomplete.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Quality Assurance System (Sections 70 - 76)</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Critical:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>There was no Quality Assurance System in place.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Major:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>There was no policy or procedure to describe when testing of both the infant donor and the mother is required.</li> 
 <li>The establishment did not have a procedure in place for conducting the donor suitability assessment.</li> 
 <li>The deceased donor screening policy did not provide guidance on how to assess responses to questions in the medical, social and behavioural history questionnaire that were marked as "unknown".</li> 
 <li>There was no procedure in place for investigating, quarantining of CTO (if required) and reporting suspected error and accident to other implicated establishments as required.</li> 
 <li>The establishment had not conducted an audit to verify that all activities carried out comply with the CTO Regulations and with its standard operating procedures, by a person who does not have direct responsibility for the activities being audited.</li> 
 <li>There was no evidence to indicate that the establishment reviewed the standard operating procedures impacting the safety of the CTO every two years.</li> 
 <li>There was no policy or procedure in place to apply exceptional distribution provisions as required by the CTO Regulations.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><strong>Minor:</strong></p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul class="lst-spcd"> 
 <li>Although it was documented that the designated hospital staff are trained and knowledgeable on labelling requirements, a copy of the current labelling procedure was not available at the locations where the activities were performed.</li> 
 <li>The "Record" section of the standard operating procedures did not indicate to keep the records for the required 10 years.</li> 
</ul>
    


</div>

</div>
                
            <section class="pagedetails">
    <h2 class="wb-inv">Page details</h2>
    
        <dl id="wb-dtmd">
    <dt>Date modified:</dt>
    <dd><time property="dateModified">2011-12-08</time></dd>
</dl>
</section>

        </main>
        <nav class="wb-sec col-md-3 col-md-pull-9" typeof="SiteNavigationElement" id="wb-sec">
            <div>
    <h2 id="wb-sec-h" class="wb-inv">Section Menu</h2>
    <section class="list-group menu list-unstyled">
        <h3 class="wb-navcurr"><a href="../compliance-enforcement.html">Compliance and Enforcement</a></h3>
        <ul class="list-group menu list-unstyled">
            <li><a href="consultation-summary-notice-stakeholders-atypical-active-pharmaceutical-ingredients.1584.dela" class="list-group-item">Consultation Summary: Notice to Stakeholders - Implementation of Establishment Licensing Requirements for Atypical Active Pharmaceutical Ingredients</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2009-edition-0001.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP) Guidelines - 2009 Edition (GUI-0001)</a>
                
            </li>
        
            <li><a href="creation-regulatory-framework-implementation-good-manufacturing-practices-active.html" class="list-group-item">Creation of a Regulatory Framework for the Implementation of Good Manufacturing Practices for Active Pharmaceutical Ingredients (API) - 2009 Health Canada Consultation Notice</a>
                
            </li>
        
            <li><a href="creation-regulatory-framework-implementation-good-manufacturing-practices-active-pharmaceutic" class="list-group-item">Creation of a Regulatory Framework for the Implementation of Good Manufacturing Practices for Active Pharmaceutical Ingredients (API) - 2009 Health Canada Consultation Document</a>
                
            </li>
        
            <li><a href="drug-establishments-reviewing-good-manufacturing-practices-inspection-program.html" class="list-group-item">ARCHIVED - Drug Establishments: Reviewing the Good Manufacturing Practices Inspection Program</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-program-review.html" class="list-group-item">ARCHIVED - Consultation on Good Manufacturing Practices - Program Review</a>
                
            </li>
        
            <li><a href="draft-guide-risk-classification-observations-made-inspections-blood-establishments.1582.delay" class="list-group-item">ARCHIVED - Consultation: Draft Guide for the Risk Classification of Observations Made During Inspections of Blood Establishments (Revised)</a>
                
            </li>
        
            <li><a href="draft-documents-drug-good-manufacturing-practices-inspection-program-0001-related.1581.delaye" class="list-group-item">ARCHIVED - Consultation: Draft Documents for Drug Good Manufacturing Practices (GMP) Inspection Program (GUI-0001 Related)</a>
                
            </li>
        
            <li><a href="regulations-amending-food-drug-regulations-1447.html" class="list-group-item">ARCHIVED - Consultation: Regulations Amending the Food and Drug Regulations 1447 - Good Manufacturing Practices</a>
                
            </li>
        
            <li><a href="regulations-amending-food-drug-regulations-1447-good-manufacturing-practices-2009.1587.delaye" class="list-group-item">ARCHIVED - Avis : Consultation: Regulations Amending the Food and Drug Regulations 1447 - Good Manufacturing Practices</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2010-consultation-registration-form.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP)/Establishment Licence (EL) Information Sessions (Registration Form)</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2010-consultation-notice.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP) - Establishment Licence (EL) Information Sessions</a>
                
            </li>
        
            <li><a href="cleaning-validation-guidance-0028-consultation.html" class="list-group-item">Consultation: Cleaning Validation Guidance (GUI-0028)</a>
                
            </li>
        
            <li><a href="guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-cons" class="list-group-item wb-navcurr">Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101)</a>
                
            </li>
        
            <li><a href="draft-guidance-good-manufacturing-practices-active-pharmaceutical-ingredients-apis-guidelines" class="list-group-item">Consultation: Draft Guidance on Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) Guidelines (GUI-0104)</a>
                
            </li>
        
            <li><a href="survey-constituencies-input-development-question-answer-document.html" class="list-group-item">Consultation - Invitation to Participate in the Survey for ICH Q7 Constituencies: Input for Development of a Question and Answer Document</a>
                
            </li>
        
            <li><a href="notice-stakeholders-implementation-establishment-licensing-requirements-atypical-active-pharm" class="list-group-item">Notice to Stakeholders - Implementation of Establishment Licensing Requirements for Atypical Active Pharmaceutical Ingredients</a>
                
            </li>
        
            <li><a href="consultation-atypical-active-pharmaceutical-ingredients-list.html" class="list-group-item">Consultation on the Atypical Active Pharmaceutical Ingredients List</a>
                
            </li>
        
            <li><a href="consultation-draft-documents-medical-devices-program.html" class="list-group-item">Consultation: Draft Documents for Medical Devices Program</a>
                
            </li>
        
            <li><a href="notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practi" class="list-group-item">Notice to Stakeholders –Release of Guidance Documents for Consultation: Various good manufacturing practices and drug establishment licensing guidance documents</a>
                
            </li>
        
            <li><a href="consultation-atypical-active-pharmaceutical-ingredients-veterinary-use-list.html" class="list-group-item">Consultation on the List of Atypical Active Pharmaceutical Ingredients for Veterinary Use</a>
                
            </li>
        
            <li><a href="drug-natural-health-products-recall-guide.html" class="list-group-item">Drug and natural health products recall guide consultation</a>
                
            </li>
        
            <li><a href="validation-cleaning-0028-drug-dosage-form-0029.html" class="list-group-item">Notice to stakeholders - Release of draft guidance documents for consultation: Cleaning validation guide (GUI-0028) and Guide to validating drug dosage forms (GUI-0029)</a>
                
            </li>
        
            <li><a href="manufacturing-active-pharmaceutical-ingredients-gui-0104.html" class="list-group-item">Notice to Stakeholders - Release of Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104) for Consultation</a>
                
            </li>
        
            <li><a href="environmental-control-drugs-storage-transportation-gui-0069.html" class="list-group-item">Notice to stakeholders - Release of draft guidance document for consultation: Guidelines for environmental control of drugs during storage and transportation (GUI-0069)</a>
                
            </li>
        
            <li><a href="draft-guidance-annex-4-good-manufacturing-practices-guide-veterinary-drugs.html" class="list-group-item">Notice to stakeholders – Release of draft guidance document for consultation: Annex 4 to the Good manufacturing practices guide – Veterinary drugs</a>
                
            </li>
        
            <li><a href="notice-draft-guide-manufacturing-medicinal-products-annex-1.html" class="list-group-item">Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice for Medicinal Products Annex 1 Manufacture of Sterile Medicinal Products - 3-month consultation period</a>
                
            </li>
        
            <li><a href="notice-draft-guidance-consultation-annex-3a-good-manufacturing-practices-schedule-c-drugs.156" class="list-group-item">Notice to stakeholders – Release of draft guidance document for consultation: Annex 3A to the Good Manufacturing Practices Guide</a>
                
            </li>
        </ul>
    </section>
 <!-- comment --></div>
        </nav>
    </div>
</div>





    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    

</div>

    




    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    
        
        
        <div class="global-footer">
    <footer id="wb-info">
	    <h2 class="wb-inv">About this site</h2>
    	<div class="gc-contextual"><div class="container">
    <nav>
        <h3>Health Canada</h3>
        <ul class="list-col-xs-1 list-col-sm-2 list-col-md-3">
            <li><a href="https://www.canada.ca/en/health-canada/corporate/contact-us.html">Contact us</a></li>
        </ul>
    </nav>
</div></div>	
        <div class="gc-main-footer">
			<div class="container">
	<nav>
	<h3>Government of Canada</h3>
	<ul class="list-unstyled colcount-sm-2 colcount-md-3">
		<li><a href="https://www.canada.ca/en/contact.html">All contacts</a></li>
		<li><a href="https://www.canada.ca/en/government/dept.html">Departments and agencies</a></li>
		<li><a href="https://www.canada.ca/en/government/system.html">About government</a></li>
	</ul>
	<h4><span class="wb-inv">Themes and topics</span></h4>
	<ul class="list-unstyled colcount-sm-2 colcount-md-3">			
		<li><a href="https://www.canada.ca/en/services/jobs.html">Jobs</a></li>
		<li><a href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
		<li><a href="https://travel.gc.ca/">Travel and tourism</a></li>
		<li><a href="https://www.canada.ca/en/services/business.html">Business</a></li>
		<li><a href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
		<li><a href="https://www.canada.ca/en/services/health.html">Health</a></li>
		<li><a href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
		<li><a href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
		<li><a href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
		<li><a href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
		<li><a href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
		<li><a href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
		<li><a href="https://www.international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
		<li><a href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
		<li><a href="https://www.canada.ca/en/services/science.html">Science and innovation</a></li>
		<li><a href="https://www.canada.ca/en/services/indigenous-peoples.html">Indigenous Peoples</a></li>
		<li><a href="https://www.canada.ca/en/services/veterans-military.html">Veterans and military</a></li>
		<li><a href="https://www.canada.ca/en/services/youth.html">Youth</a></li>
	</ul>
	</nav>
</div>
	
        </div>
        <div class="gc-sub-footer">
            <div class="container d-flex align-items-center">
            <nav>
                <h3 class="wb-inv">Government of Canada Corporate</h3>
                <ul>
                
                    		<li><a href="https://www.canada.ca/en/social.html">Social media</a></li>
		<li><a href="https://www.canada.ca/en/mobile.html">Mobile applications</a></li>
		<li><a href="https://www.canada.ca/en/government/about.html">About Canada.ca</a></li>
                
                <li><a href="https://www.canada.ca/en/transparency/terms.html">Terms and conditions</a></li>
                <li><a href="https://www.canada.ca/en/transparency/privacy.html">Privacy</a></li>
                </ul>
            </nav>
                <div class="wtrmrk align-self-end">
                    <img src="https://www.canada.ca/etc/designs/canada/wet-boew/assets/wmms-blk.svg" alt="Symbol of the Government of Canada"/>
                </div>
            </div>
        </div>
    </footer>

</div>

    

</div>

    




    







    <script type="text/javascript">_satellite.pageBottom();</script>






<script src="../../../../../../../ajax.googleapis.com/ajax/libs/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/ep-pp.min.js"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/wet-boew.min.js"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/theme.min.js"></script>




</body>

<!-- Mirrored from www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/compliance-enforcement/guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-consultation.html by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 03 Apr 2025 21:45:48 GMT -->
</html>
